Hormonothérapie des cancers du sein
- 1 November 2011
- journal article
- review article
- Published by Elsevier in Bulletin du Cancer
- Vol. 98 (11) , 1311-1319
Abstract
The nuclear estrogen receptors (ER) are the major targets for endocrine treatment of hormone-dependent breast cancers. Hormone therapy blocked endogenous estrogen activation of ER, either by competitive inhibition of endogenous estrogens (selective estrogen receptor modulators - SERM or selective estrogen receptor down regulators - SERD) or by inhibition of estrogen synthesis (aromatase inhibitors) from adrenal androgens in post-menopausal women. The efficacy of these treatments has been shown on large series of breast cancer patients. However de novo or acquired resistance to treatment occurs. The better knowledge of the mechanism of action of such treatment may help to better understand them, and also for the determinism of adverse side effects of the different class of molecules.Keywords
This publication has 45 references indexed in Scilit:
- Selective estrogen receptor modulationCancer Cell, 2004
- Is Tamoxifen the Rosetta Stone for Breast Cancer?JNCI: Journal of the National Cancer Institute, 2003
- Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart DiseaseJNCI: Journal of the National Cancer Institute, 2001
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- Molecular basis of agonism and antagonism in the oestrogen receptorNature, 1997
- Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor αJournal of Biological Chemistry, 1997
- ERβ: Identification and characterization of a novel human estrogen receptorFEBS Letters, 1996
- Cloning of a novel receptor expressed in rat prostate and ovary.Proceedings of the National Academy of Sciences, 1996
- Molecular mechanisms of antiestrogen action in breast cancerBreast Cancer Research and Treatment, 1994
- Carcinogenesis: A superfamily of potentially oncogenic hormone receptorsNature, 1986